JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$3.21B |
| 2 |
Arthur J. Gallagher & Co
AJG
|
+$2.24B |
| 3 |
Walt Disney
DIS
|
+$2.18B |
| 4 |
Walmart Inc
WMT
|
+$1.96B |
| 5 |
McDonald's
MCD
|
+$1.91B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$2.77B |
| 2 |
JPMorgan BetaBuilders Europe ETF
BBEU
|
+$2.64B |
| 3 |
Vanguard Long-Term Treasury ETF
VGLT
|
+$2.5B |
| 4 |
iShares Broad USD High Yield Corporate Bond ETF
USHY
|
+$2.23B |
| 5 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$2.06B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 24.61% |
| 2 | Technology | 23.17% |
| 3 | Financials | 10.12% |
| 4 | Consumer Discretionary | 9.84% |
| 5 | Healthcare | 7.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
KLRS
6326
Kalaris Therapeutics
KLRS
$67.8M
| $3.43K | ﹤0.01% |
355
+260
| +274% | +$3.93K |
2020 Q3
17 quarters
|
|
|
ASRT
6327
DELISTED
Assertio
ASRT
| $3.4K | ﹤0.01% |
260
-439
| -63% | -$6.54K |
2015 Q4
36 quarters
|
|
6328
FT Vest US Equity Deep Buffer ETF June
DJUN
$358M
| $3.33K | ﹤0.01% |
+77
| New | +$3.33K |
2024 Q4
0 quarters
|
|
|
NYXH
6329
Nyxoah
NYXH
$135M
| $3.21K | ﹤0.01% |
401
-293
| -42% | -$2.56K |
2024 Q1
3 quarters
|
|
6330
CALL
MP Materials
MP
$8.21B
| $3.12K | ﹤0.01% |
200
| – | – |
2024 Q2
2 quarters
|
|
6331
SonicShares Global Shipping ETF
BOAT
$138M
| $3.1K | ﹤0.01% |
111
| – | – |
2024 Q2
2 quarters
|
|
|
CLEU
6332
DELISTED
China Liberal Education Holdings
CLEU
| $3.1K | ﹤0.01% |
+9
| New | +$2.58K |
2024 Q4
0 quarters
|
|
|
KIO
6333
KKR Income Opportunities Fund
KIO
$421M
| $3.08K | ﹤0.01% |
230
| – | – |
2023 Q1
7 quarters
|
|
6334
Red Robin
RRGB
$142M
| $3.07K | ﹤0.01% |
560
| – | – |
2016 Q4
32 quarters
|
|
6335
Northern Trust High Yield Value-Scored Bond ETF
HYGV
$1.02B
| $3.05K | ﹤0.01% |
75
-439
| -85% | -$18.1K |
2024 Q1
3 quarters
|
|
|
DECAU
6336
DELISTED
Denali Capital Acquisition Corp. Unit
DECAU
| $3.02K | ﹤0.01% |
259
| – | – |
2024 Q1
3 quarters
|
|
6337
Enlivex Ltd
ENLV
$8.42M
| $3K | ﹤0.01% |
171
+50
| +41% | +$973 |
2022 Q4
8 quarters
|
|
|
OPTN
6338
DELISTED
OptiNose
OPTN
| $3K | ﹤0.01% |
449
-19
| -4% | -$167 |
2017 Q4
28 quarters
|
|
6339
Protalix BioTherapeutics
PLX
$216M
| $3K | ﹤0.01% |
1,595
| – | – |
2023 Q2
6 quarters
|
|
6340
State Street SPDR S&P International Small Cap ETF
GWX
$917M
| $2.96K | ﹤0.01% |
95
-15
| -14% | -$484 |
2020 Q2
18 quarters
|
|
|
AURE
6341
Aurelion Inc
AURE
$41M
| $2.95K | ﹤0.01% |
+227
| New | +$2.44K |
2024 Q4
0 quarters
|
|
6342
State Street Multi-Asset Real Return ETF
RLY
$1.38B
| $2.94K | ﹤0.01% |
109
-16
| -13% | -$454 |
2024 Q2
2 quarters
|
|
|
ZOM
6343
DELISTED
Zomedica Corp.
ZOM
| $2.93K | ﹤0.01% |
24,410
+23,497
| +2,574% | +$2.96K |
2021 Q1
15 quarters
|
|
6344
Nuveen ESG International Developed Markets Equity ETF
NUDM
$726M
| $2.92K | ﹤0.01% |
97
-1,262
| -93% | -$40.4K |
2023 Q1
7 quarters
|
|
6345
AllianzIM U.S. Equity Buffer20 Feb ETF
FEBW
$199M
| $2.91K | ﹤0.01% |
+93
| New | +$2.86K |
2024 Q4
0 quarters
|
|
|
OKUR
6346
OnKure Therapeutics
OKUR
$103M
| $2.9K | ﹤0.01% |
337
-430
| -56% | -$6.51K |
2022 Q3
9 quarters
|
|
6347
Roundhill Sports Betting & iGaming ETF
BETZ
$40.8M
| $2.88K | ﹤0.01% |
152
+82
| +117% | +$1.58K |
2021 Q1
15 quarters
|
|
6348
Harbor Commodity All-Weather Strategy ETF
HGER
$4.79B
| $2.88K | ﹤0.01% |
+130
| New | +$2.94K |
2024 Q4
0 quarters
|
|
6349
Atara Biotherapeutics
ATRA
$84.9M
| $2.88K | ﹤0.01% |
216
-1,154
| -84% | -$12.2K |
2017 Q4
28 quarters
|
|
6350
First Trust DorseyWright DALI 1 ETF
DALI
$96.6M
| $2.83K | ﹤0.01% |
109
-4
| -4% | -$105 |
2023 Q4
4 quarters
|
|
Similar funds
JP Morgan Chase's Q4 2024 Portfolio in Review
As of Q4 2024, JP Morgan Chase held 7,917 positions worth $1.34T, up 2.1% from $1.32T the previous quarter. Its ten largest holdings account for 24% of the portfolio.
JP Morgan Chase's Q4 2024 filing shows 509 new, 3,351 increased, 2,465 reduced and 522 closed positions. Its largest new stake was Primo Brands: 3,989,501 shares worth $123M. The largest sale was Eli Lilly, an estimated $2.77B.
By sector, the portfolio is most concentrated in Miscellaneous at 25% of assets, up from 24% a quarter earlier, followed by Technology and Financials.
- JP Morgan Chase's largest Q4 2024 buy was Primo Brands: 3,989,501 shares worth $123M.
- JP Morgan Chase added most to Broadcom in Q4 2024, an estimated $3.21B increase.
- JP Morgan Chase's biggest Q4 2024 reduction was Eli Lilly, cutting an estimated $2.77B.
- JP Morgan Chase fully exited Stericycle Inc in Q4 2024, selling an estimated $183M.
- JP Morgan Chase's ten largest holdings make up 24% of its $1.34T portfolio in Q4 2024.
- JP Morgan Chase opened 509 new positions and closed 522 in Q4 2024.
- JP Morgan Chase's portfolio value rose 2.1% quarter-over-quarter to $1.34T.
Based on JP Morgan Chase's 13F filing for Q4 2024, filed 12 Feb 2025.